Rogers Christopher S, Vanoye Carlos G, Sullenger Bruce A, George Alfred L
Division of Genetic Medicine, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
J Clin Invest. 2002 Dec;110(12):1783-9. doi: 10.1172/JCI16481.
RNA repair has been proposed as a novel gene-based therapeutic strategy. Modified Tetrahymena group I intron ribozymes have been used to mediate trans-splicing of therapeutically relevant RNA transcripts, but the efficiency of the ribozyme-mediated RNA repair process has not been determined precisely and subsequent restoration of protein function has been demonstrated only by indirect means. We engineered a ribozyme that targets the mRNA of a mutant canine skeletal muscle chloride channel (cClC-1) (mutation T268M in ClC-1 causing myotonia congenita) and replaces the mutant-containing 3' portion by trans-splicing the corresponding 4-kb wild-type sequence. Repair efficiency assessed by quantitative RT-PCR was 1.2% +/- 0.1% in a population of treated cells. However, when chloride channel function was examined in single cells, a wide range of electrophysiological activity was observed, with 18% of cells exhibiting significant functional restoration and some cells exhibiting complete rescue of the biophysical phenotype. These results indicate that RNA repair can restore wild-type protein activity and reveal considerable cell-to-cell variability in ribozyme-mediated trans-splicing reaction efficiency.
RNA修复已被提议作为一种基于基因的新型治疗策略。修饰后的嗜热四膜虫I组内含子核酶已被用于介导与治疗相关的RNA转录本的反式剪接,但核酶介导的RNA修复过程的效率尚未得到精确测定,并且蛋白质功能的后续恢复仅通过间接手段得到证实。我们设计了一种核酶,它靶向突变犬骨骼肌氯离子通道(cClC-1)的mRNA(ClC-1中的T268M突变导致先天性肌强直),并通过反式剪接相应的4kb野生型序列来替换包含突变的3'部分。通过定量RT-PCR评估,在一群处理过的细胞中,修复效率为1.2%±0.1%。然而,当在单细胞中检测氯离子通道功能时,观察到了广泛的电生理活性,18%的细胞表现出显著的功能恢复,一些细胞表现出生物物理表型的完全挽救。这些结果表明RNA修复可以恢复野生型蛋白质活性,并揭示核酶介导的反式剪接反应效率在细胞间存在相当大的变异性。